{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:05:45Z","timestamp":1793379945932,"version":"4.5.0"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chongqing Science and Technology Commission of China","award":["cstc2021jcyj-jqX0006"],"award-info":[{"award-number":["cstc2021jcyj-jqX0006"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["Nos. 81922068"],"award-info":[{"award-number":["Nos. 81922068"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Support Program of Guizhou province","award":["NO.[2021]Genaral410"],"award-info":[{"award-number":["NO.[2021]Genaral410"]}]},{"name":"Natural Science Foundation of Guizhou Provice","award":["Grant No. Qiankehejichu (2019)1343"],"award-info":[{"award-number":["Grant No. Qiankehejichu (2019)1343"]}]},{"name":"Foundation of Honghuagang District Science and Technology Bureau","award":["Grant No. Zunhongkeheshezi (2021) 05"],"award-info":[{"award-number":["Grant No. Zunhongkeheshezi (2021) 05"]}]},{"name":"PhD Start-up Foundation of Zunyi Medical University","award":["Grant No. F-811"],"award-info":[{"award-number":["Grant No. F-811"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The mRNA vaccine technology was developed rapidly during the global pandemic of COVID-19. The crucial role of the COVID-19 mRNA vaccine in preventing viral infection also have been beneficial to the exploration and application of other viral mRNA vaccines, especially for non-replication structure mRNA vaccines of viral disease with outstanding research results. Therefore, this review pays attention to the existing mRNA vaccines, which are of great value for candidates for clinical applications in viral diseases. We provide an overview of the optimization of the mRNA vaccine development process as well as the good immune efficacy and safety shown in clinical studies. In addition, we also provide a brief description of the important role of mRNA immunomodulators in the treatment of viral diseases. After that, it will provide a good reference or strategy for research on mRNA vaccines used in clinical medicine with more stable structures, higher translation efficiency, better immune efficacy and safety, shorter production time, and lower production costs than conditional vaccines to be used as preventive or therapeutic strategy for the control of viral diseases in the future.<\/jats:p>","DOI":"10.1186\/s12985-023-02023-0","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T13:02:42Z","timestamp":1680872562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines"],"prefix":"10.1186","volume":"20","author":[{"given":"Xiao","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youcai","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingrui","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuancheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongai","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"issue":"1","key":"2023_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1080\/22221751.2021.1898291","volume":"10","author":"KK-W To","year":"2021","unstructured":"To KK-W, Sridhar S, Chiu KH-Y, Hung DL-L, Li X, Hung IF-N, Tam AR, Chung TW-H, Chan JF-W, Zhang AJ-X, et al. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg Microbes Infect. 2021;10(1):507\u201335.","journal-title":"Emerg Microbes Infect"},{"issue":"6499","key":"2023_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","volume":"369","author":"Q Gao","year":"2020","unstructured":"Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77\u201381.","journal-title":"Science"},{"issue":"24","key":"2023_CR3","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","volume":"383","author":"C Keech","year":"2020","unstructured":"Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, et al. Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383(24):2320\u201332.","journal-title":"N Engl J Med"},{"issue":"7845","key":"2023_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41586-020-3035-9","volume":"590","author":"L Sanchez-Felipe","year":"2021","unstructured":"Sanchez-Felipe L, Vercruysse T, Sharma S, Ma J, Lemmens V, Van Looveren D, Arkalagud Javarappa MP, Boudewijns R, Malengier-Devlies B, Liesenborghs L, et al. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature. 2021;590(7845):320\u20135.","journal-title":"Nature"},{"key":"2023_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173751","volume":"892","author":"K Rawat","year":"2021","unstructured":"Rawat K, Kumari P, Saha L. COVID-19 vaccine: a recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol. 2021;892: 173751.","journal-title":"Eur J Pharmacol"},{"key":"2023_CR6","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","volume":"10","author":"C Zhang","year":"2019","unstructured":"Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019;10:594.","journal-title":"Front Immunol"},{"issue":"10","key":"2023_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin U, Karik\u00f3 K, T\u00fcreci \u00d6. mRNA-based therapeutics\u2013developing a new class of drugs. Nat Rev Drug Discovery. 2014;13(10):759\u201380.","journal-title":"Nat Rev Drug Discovery"},{"issue":"6857","key":"2023_CR8","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/35099560","volume":"413","author":"L Alexopoulou","year":"2001","unstructured":"Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732\u20138.","journal-title":"Nature"},{"issue":"5663","key":"2023_CR9","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1126\/science.1093616","volume":"303","author":"SS Diebold","year":"2004","unstructured":"Diebold SS, Kaisho T, Hemmi H, Akira S. Reis e Sousa C: Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303(5663):1529\u201331.","journal-title":"Science"},{"issue":"5663","key":"2023_CR10","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1126\/science.1093620","volume":"303","author":"F Heil","year":"2004","unstructured":"Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303(5663):1526\u20139.","journal-title":"Science"},{"issue":"2","key":"2023_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Karik\u00f3","year":"2005","unstructured":"Karik\u00f3 K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165\u201375.","journal-title":"Immunity"},{"issue":"18","key":"2023_CR12","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.3390\/ijms21186582","volume":"21","author":"S Xu","year":"2020","unstructured":"Xu S, Yang K, Li R, Zhang L. mRNA vaccine era-mechanisms, drug platform and clinical prospection. Int J Mol Sci. 2020;21(18):6582.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2023_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4155\/tde-2016-0006","volume":"7","author":"AM Reichmuth","year":"2016","unstructured":"Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7(5):319\u201334.","journal-title":"Ther Deliv"},{"issue":"27","key":"2023_CR14","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, P\u00e9rez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"issue":"4","key":"2023_CR15","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.bbrc.2005.12.105","volume":"340","author":"M Mockey","year":"2006","unstructured":"Mockey M, Gon\u00e7alves C, Dupuy FP, Lemoine FM, Pichon C, Midoux P. mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level. Biochem Biophys Res Commun. 2006;340(4):1062\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"2023_CR16","first-page":"1486","volume":"7","author":"J Stepinski","year":"2001","unstructured":"Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads RE. Synthesis and properties of mRNAs containing the novel \u201canti-reverse\u201d cap analogs 7-methyl(3\u2019-O-methyl)GpppG and 7-methyl (3\u2019-deoxy)GpppG. RNA. 2001;7(10):1486\u201395.","journal-title":"RNA"},{"issue":"6525","key":"2023_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1126\/science.aay3638","volume":"371","author":"C Krienke","year":"2021","unstructured":"Krienke C, Kolb L, Diken E, Streuber M, Kirchhoff S, Bukur T, Akilli-\u00d6zt\u00fcrk \u00d6, Kranz Lena M, Berger H, Petschenka J, et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 2021;371(6525):145\u201353.","journal-title":"Science"},{"issue":"5","key":"2023_CR18","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1093\/nar\/gkt1321","volume":"42","author":"P Kumar","year":"2014","unstructured":"Kumar P, Sweeney TR, Skabkin MA, Skabkina OV, Hellen CUT, Pestova TV. Inhibition of translation by IFIT family members is determined by their ability to interact selectively with the 5\u2019-terminal regions of cap0-, cap1- and 5\u2019ppp- mRNAs. Nucleic Acids Res. 2014;42(5):3228\u201345.","journal-title":"Nucleic Acids Res"},{"key":"2023_CR19","doi-asserted-by":"publisher","first-page":"14630","DOI":"10.1038\/ncomms14630","volume":"8","author":"N Pardi","year":"2017","unstructured":"Pardi N, Secreto AJ, Shan X, Debonera F, Glover J, Yi Y, Muramatsu H, Ni H, Mui BL, Tam YK, et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun. 2017;8:14630\u201314630.","journal-title":"Nat Commun"},{"key":"2023_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.gene.2019.05.008","volume":"707","author":"F Zarghampoor","year":"2019","unstructured":"Zarghampoor F, Azarpira N, Khatami SR, Behzad-Behbahani A, Foroughmand AM. Improved translation efficiency of therapeutic mRNA. Gene. 2019;707:231\u20138.","journal-title":"Gene"},{"issue":"12","key":"2023_CR21","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","volume":"27","author":"A August","year":"2021","unstructured":"August A, Attarwala HZ, Himansu S, Kalidindi S, Lu S, Pajon R, Han S, Lecerf JM, Tomassini JE, Hard M, et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat Med. 2021;27(12):2224\u201333.","journal-title":"Nat Med"},{"issue":"8","key":"2023_CR22","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","volume":"39","author":"C Aldrich","year":"2021","unstructured":"Aldrich C, Leroux-Roels I, Huang KB, Bica MA, Loeliger E, Schoenborn-Kellenberger O, Walz L, Leroux-Roels G, von Sonnenburg F, Oostvogels L. Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial. Vaccine. 2021;39(8):1310\u20138.","journal-title":"Vaccine"},{"issue":"1","key":"2023_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13273-021-00171-4","volume":"18","author":"SC Kim","year":"2022","unstructured":"Kim SC, Sekhon SS, Shin WR, Ahn G, Cho BK, Ahn JY, Kim YH. Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Mol Cell Toxicol. 2022;18(1):1\u20138.","journal-title":"Mol Cell Toxicol"},{"issue":"1","key":"2023_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-021-01311-z","volume":"20","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X. mRNA vaccine: a potential therapeutic strategy. Mol Cancer. 2021;20(1):33.","journal-title":"Mol Cancer"},{"key":"2023_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","volume":"5","author":"NAC Jackson","year":"2020","unstructured":"Jackson NAC, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines. 2020;5:11.","journal-title":"NPJ Vaccines"},{"issue":"3","key":"2023_CR26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/0092-8674(85)90200-4","volume":"40","author":"J Pelletier","year":"1985","unstructured":"Pelletier J, Sonenberg N. Insertion mutagenesis to increase secondary structure within the 5\u2019 noncoding region of a eukaryotic mRNA reduces translational efficiency. Cell. 1985;40(3):515\u201326.","journal-title":"Cell"},{"issue":"6292","key":"2023_CR27","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1126\/science.aad9868","volume":"352","author":"AG Hinnebusch","year":"2016","unstructured":"Hinnebusch AG, Ivanov IP, Sonenberg N. Translational control by 5\u2019-untranslated regions of eukaryotic mRNAs. Science. 2016;352(6292):1413\u20136.","journal-title":"Science"},{"issue":"6","key":"2023_CR28","first-page":"756","volume":"15","author":"KH Asrani","year":"2018","unstructured":"Asrani KH, Farelli JD, Stahley MR, Miller RL, Cheng CJ, Subramanian RR, Brown JM. Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA. RNA Biol. 2018;15(6):756\u201362.","journal-title":"RNA Biol"},{"key":"2023_CR29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1146\/annurev-genet-120116-024704","volume":"51","author":"C Mayr","year":"2017","unstructured":"Mayr C. Regulation by 3\u2019-untranslated regions. Annu Rev Genet. 2017;51:171\u201394.","journal-title":"Annu Rev Genet"},{"issue":"1","key":"2023_CR30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1128\/MCB.16.1.146","volume":"16","author":"RL Tanguay","year":"1996","unstructured":"Tanguay RL, Gallie DR. Translational efficiency is regulated by the length of the 3\u2019 untranslated region. Mol Cell Biol. 1996;16(1):146\u201356.","journal-title":"Mol Cell Biol"},{"issue":"13","key":"2023_CR31","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","volume":"108","author":"S Holtkamp","year":"2006","unstructured":"Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, T\u00fcreci O, Sahin U. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006;108(13):4009\u201317.","journal-title":"Blood"},{"key":"2023_CR32","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.copbio.2021.09.016","volume":"73","author":"E Kon","year":"2022","unstructured":"Kon E, Elia U, Peer D. Principles for designing an optimal mRNA lipid nanoparticle vaccine. Curr Opin Biotechnol. 2022;73:329\u201336.","journal-title":"Curr Opin Biotechnol"},{"key":"2023_CR33","doi-asserted-by":"crossref","unstructured":"Mignone F, Gissi C, Liuni S, Pesole G. Untranslated regions of mRNAs. Genome Biol. 2002;3(3):REVIEWS0004-REVIEWS0004.","DOI":"10.1186\/gb-2002-3-3-reviews0004"},{"issue":"7","key":"2023_CR34","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.tibtech.2004.04.006","volume":"22","author":"C Gustafsson","year":"2004","unstructured":"Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol. 2004;22(7):346\u201353.","journal-title":"Trends Biotechnol"},{"issue":"3","key":"2023_CR35","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","volume":"26","author":"S Linares-Fern\u00e1ndez","year":"2020","unstructured":"Linares-Fern\u00e1ndez S, Lacroix C, Exposito JY, Verrier B. Tailoring mRNA vaccine to balance innate\/adaptive immune response. Trends Mol Med. 2020;26(3):311\u201323.","journal-title":"Trends Mol Med"},{"issue":"6","key":"2023_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0040180","volume":"4","author":"G Kudla","year":"2006","unstructured":"Kudla G, Lipinski L, Caffin F, Helwak A, Zylicz M. High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol. 2006;4(6): e180.","journal-title":"PLoS Biol"},{"issue":"6","key":"2023_CR37","doi-asserted-by":"publisher","first-page":"e0004746","DOI":"10.1371\/journal.pntd.0004746","volume":"10","author":"M Schnee","year":"2016","unstructured":"Schnee M, Vogel AB, Voss D, Petsch B, Baumhof P, Kramps T, Stitz L. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl Trop Dis. 2016;10(6):e0004746\u2013e0004746.","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"2023_CR38","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/nbt.2436","volume":"30","author":"B Petsch","year":"2012","unstructured":"Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen KJ, Stitz L, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol. 2012;30(12):1210\u20136.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"2023_CR39","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/nsmb.3499","volume":"24","author":"SA Lima","year":"2017","unstructured":"Lima SA, Chipman LB, Nicholson AL, Chen YH, Yee BA, Yeo GW, Coller J, Pasquinelli AE. Short poly(A) tails are a conserved feature of highly expressed genes. Nat Struct Mol Biol. 2017;24(12):1057\u201363.","journal-title":"Nat Struct Mol Biol"},{"issue":"4","key":"2023_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.21","volume":"5","author":"AE Grier","year":"2016","unstructured":"Grier AE, Burleigh S, Sahni J, Clough CA, Cardot V, Choe DC, Krutein MC, Rawlings DJ, Jensen MC, Scharenberg AM, et al. pEVL: a linear plasmid for generating mRNA IVT templates with extended encoded poly(a) sequences. Mol Ther Nucleic Acids. 2016;5(4): e306.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2023_CR41","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.omtn.2021.10.007","volume":"26","author":"S Linares-Fern\u00e1ndez","year":"2021","unstructured":"Linares-Fern\u00e1ndez S, Moreno J, Lambert E, Mercier-Gouy P, Vachez L, Verrier B, Exposito J-Y. Combining an optimized mRNA template with a double purification process allows strong expression of in vitro transcribed mRNA. Mol Ther Nucleic Acids. 2021;26:945\u201356.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7481","key":"2023_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature12730","volume":"505","author":"X Wang","year":"2014","unstructured":"Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, Fu Y, Parisien M, Dai Q, Jia G, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(7481):117\u201320.","journal-title":"Nature"},{"issue":"6","key":"2023_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa070","volume":"48","author":"CJC Parr","year":"2020","unstructured":"Parr CJC, Wada S, Kotake K, Kameda S, Matsuura S, Sakashita S, Park S, Sugiyama H, Kuang Y, Saito H. N 1-Methylpseudouridine substitution enhances the performance of synthetic mRNA switches in cells. Nucleic Acids Res. 2020;48(6): e35.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2023_CR44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12943-020-01166-w","volume":"19","author":"W Liang","year":"2020","unstructured":"Liang W, Lin Z, Du C, Qiu D, Zhang Q. mRNA modification orchestrates cancer stem cell fate decisions. Mol Cancer. 2020;19(1):38.","journal-title":"Mol Cancer"},{"key":"2023_CR45","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.omtm.2020.07.013","volume":"18","author":"M Zhang","year":"2020","unstructured":"Zhang M, Sun J, Li M, Jin X. Modified mRNA-LNP vaccines confer protection against experimental DENV-2 infection in mice. Mol Therapy Methods Clin Develop. 2020;18:702\u201312.","journal-title":"Mol Therapy Methods Clin Develop"},{"issue":"11","key":"2023_CR46","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Karik\u00f3","year":"2008","unstructured":"Karik\u00f3 K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833\u201340.","journal-title":"Mol Ther"},{"key":"2023_CR47","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-1-4939-6481-9_6","volume":"1499","author":"N Pardi","year":"2017","unstructured":"Pardi N, Weissman D. Nucleoside modified mRNA vaccines for infectious diseases. Methods Mol Biol (Clifton, NJ). 2017;1499:109\u201321.","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"issue":"11","key":"2023_CR48","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1074\/jbc.270.11.6298","volume":"270","author":"FJ Triana-Alonso","year":"1995","unstructured":"Triana-Alonso FJ, Dabrowski M, Wadzack J, Nierhaus KH. Self-coded 3\u2019-extension of run-off transcripts produces aberrant products during in vitro transcription with T7 RNA polymerase. J Biol Chem. 1995;270(11):6298\u2013307.","journal-title":"J Biol Chem"},{"issue":"21","key":"2023_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr695","volume":"39","author":"K Karik\u00f3","year":"2011","unstructured":"Karik\u00f3 K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011;39(21): e142.","journal-title":"Nucleic Acids Res"},{"key":"2023_CR50","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-1-62703-260-5_3","volume":"969","author":"D Weissman","year":"2013","unstructured":"Weissman D, Pardi N, Muramatsu H, Karik\u00f3 K. HPLC purification of in vitro transcribed long RNA. Methods Mol Biol (Clifton, NJ). 2013;969:43\u201354.","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"key":"2023_CR51","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","volume":"15","author":"M Baiersd\u00f6rfer","year":"2019","unstructured":"Baiersd\u00f6rfer M, Boros G, Muramatsu H, Mahiny A, Vlatkovic I, Sahin U, Karik\u00f3 K. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol Ther Nucleic Acids. 2019;15:26\u201335.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"Pt A","key":"2023_CR52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijbiomac.2018.05.198","volume":"118","author":"S Borkotoky","year":"2018","unstructured":"Borkotoky S, Murali A. The highly efficient T7 RNA polymerase: a wonder macromolecule in biological realm. Int J Biol Macromol. 2018;118(Pt A):49\u201356.","journal-title":"Int J Biol Macromol"},{"issue":"12","key":"2023_CR53","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1261\/rna.076778.120","volume":"26","author":"LFM Passalacqua","year":"2020","unstructured":"Passalacqua LFM, Dingilian AI, Lupt\u00e1k A. Single-pass transcription by T7 RNA polymerase. RNA. 2020;26(12):2062\u201371.","journal-title":"RNA"},{"issue":"3","key":"2023_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100999","volume":"297","author":"E Cavac","year":"2021","unstructured":"Cavac E, Ram\u00edrez-Tapia LE, Martin CT. High-salt transcription of DNA cotethered with T7 RNA polymerase to beads generates increased yields of highly pure RNA. J Biol Chem. 2021;297(3): 100999.","journal-title":"J Biol Chem"},{"key":"2023_CR55","doi-asserted-by":"crossref","unstructured":"M.Miller, Alvizo O, Chng C, Jenne S, Mayo M, Mukherjee A, Sundseth S, Chinthala A, Penfield J, Riggins J et al. An engineered T7 RNA polymerase for efficient co-transcriptional capping with reduced dsRNA byproducts in mRNA synthesis. 2022.","DOI":"10.1101\/2022.09.01.506264"},{"issue":"1","key":"2023_CR56","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1080\/15476286.2022.2139113","volume":"19","author":"H Xia","year":"2022","unstructured":"Xia H, Yu B, Jiang Y, Cheng R, Lu X, Wu H, Zhu B. Psychrophilic phage VSW-3 RNA polymerase reduces both terminal and full-length dsRNA byproducts in in vitro transcription. RNA Biol. 2022;19(1):1130\u201342.","journal-title":"RNA Biol"},{"issue":"sup1","key":"2023_CR57","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/15476286.2021.1954808","volume":"18","author":"H Wu","year":"2021","unstructured":"Wu H, Wei T, Yu B, Cheng R, Huang F, Lu X, Yan Y, Wang X, Liu C, Zhu B. A single mutation attenuates both the transcription termination and RNA-dependent RNA polymerase activity of T7 RNA polymerase. RNA Biol. 2021;18(sup1):451\u201366.","journal-title":"RNA Biol"},{"issue":"5","key":"2023_CR58","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/biomedicines9050530","volume":"9","author":"I Vlatkovic","year":"2021","unstructured":"Vlatkovic I. Non-Immunotherapy application of LNP-mRNA: maximizing efficacy and safety. Biomedicines. 2021;9(5):530.","journal-title":"Biomedicines"},{"issue":"4","key":"2023_CR59","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines\u2014A new era in vaccinology. Nat Rev Drug Discovery. 2018;17(4):261\u201379.","journal-title":"Nat Rev Drug Discovery"},{"key":"2023_CR60","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","volume":"217","author":"N Pardi","year":"2015","unstructured":"Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, Madden TD, Hope MJ, Weissman D. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release: Off J Control Release Soc. 2015;217:345\u201351.","journal-title":"J Control Release: Off J Control Release Soc"},{"issue":"5","key":"2023_CR61","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1021\/acs.nanolett.0c05039","volume":"21","author":"Y Yin","year":"2021","unstructured":"Yin Y, Li X, Ma H, Zhang J, Yu D, Zhao R, Yu S, Nie G, Wang H. In situ transforming RNA nanovaccines from polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy. Nano Lett. 2021;21(5):2224\u201331.","journal-title":"Nano Lett"},{"issue":"5","key":"2023_CR62","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","volume":"182","author":"NN Zhang","year":"2020","unstructured":"Zhang NN, Li XF, Deng YQ, Zhao H, Huang YJ, Yang G, Huang WJ, Gao P, Zhou C, Zhang RR, et al. A thermostable mRNA vaccine against COVID-19. Cell. 2020;182(5):1271-1283.e1216.","journal-title":"Cell"},{"issue":"5","key":"2023_CR63","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/j.ymthe.2022.02.001","volume":"30","author":"H Muramatsu","year":"2022","unstructured":"Muramatsu H, Lam K, Bajusz C, Laczk\u00f3 D, Karik\u00f3 K, Schreiner P, Martin A, Lutwyche P, Heyes J, Pardi N. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. Mol Ther. 2022;30(5):1941\u201351.","journal-title":"Mol Ther"},{"key":"2023_CR64","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3389\/fimmu.2020.02037","volume":"11","author":"E Mortaz","year":"2020","unstructured":"Mortaz E, Tabarsi P, Varahram M, Folkerts G, Adcock IM. The immune response and immunopathology of COVID-19. Front Immunol. 2020;11:2037.","journal-title":"Front Immunol"},{"issue":"3","key":"2023_CR65","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141\u201354.","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"2023_CR66","first-page":"11","volume":"7","author":"YR Guo","year":"2020","unstructured":"Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11.","journal-title":"Mil Med Res"},{"key":"2023_CR67","doi-asserted-by":"crossref","unstructured":"McLean HQ, Grijalva CG, Hanson KE, Zhu Y, Deyoe JE, Meece JK, Halasa NB, Chappell JD, Mellis AM, Reed C et al. Household transmission and clinical features of SARS-CoV-2 infections. Pediatrics 2022;149(3).","DOI":"10.1542\/peds.2021-054178"},{"issue":"2","key":"2023_CR68","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e278.","journal-title":"Cell"},{"issue":"25","key":"2023_CR69","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439\u201350.","journal-title":"N Engl J Med"},{"issue":"19","key":"2023_CR70","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","volume":"385","author":"SJ Thomas","year":"2021","unstructured":"Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, P\u00e9rez Marc G, Polack FP, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761\u201373.","journal-title":"N Engl J Med"},{"issue":"16","key":"2023_CR71","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","volume":"383","author":"KS Corbett","year":"2020","unstructured":"Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, O\u2019Connell S, Bock KW, Minai M, et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020;383(16):1544\u201355.","journal-title":"N Engl J Med"},{"issue":"5","key":"2023_CR72","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403\u201316.","journal-title":"N Engl J Med"},{"issue":"14","key":"2023_CR73","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","volume":"185","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Mateus J, Coelho CH, Dan JM, Moderbacher CR, G\u00e1lvez RI, Cortes FH, Grifoni A, Tarke A, Chang J, et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell. 2022;185(14):2434-2451.e2417.","journal-title":"Cell"},{"key":"2023_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.809244","volume":"12","author":"P Mistry","year":"2021","unstructured":"Mistry P, Barmania F, Mellet J, Peta K, Strydom A, Viljoen IM, James W, Gordon S, Pepper MS. SARS-CoV-2 variants, vaccines, and host immunity. Front Immunol. 2021;12: 809244.","journal-title":"Front Immunol"},{"issue":"3","key":"2023_CR75","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1473-3099(21)00677-0","volume":"22","author":"PG Kremsner","year":"2022","unstructured":"Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler R, Corral G, De Block EJL, Ecker L, Gabor JJ, et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial. Lancet Infect Dis. 2022;22(3):329\u201340.","journal-title":"Lancet Infect Dis"},{"issue":"7893","key":"2023_CR76","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-021-04231-6","volume":"601","author":"MS Gebre","year":"2022","unstructured":"Gebre MS, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado NB, He X, Liu J, McMahan K, Martinot A, et al. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Nature. 2022;601(7893):410\u20134.","journal-title":"Nature"},{"issue":"9","key":"2023_CR77","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1056\/NEJMc2119426","volume":"386","author":"X Zhao","year":"2022","unstructured":"Zhao X, Li D, Ruan W, Chen Z, Zhang R, Zheng A, Qiao S, Zheng X, Zhao Y, Dai L, et al. Effects of a prolonged booster interval on neutralization of omicron variant. N Engl J Med. 2022;386(9):894\u20136.","journal-title":"N Engl J Med"},{"key":"2023_CR78","doi-asserted-by":"crossref","unstructured":"Han Y, An Y, Chen Q, Xu K, Liu X, Xu S, Duan H, Vogel AB, \u015eahin U, Wang Q et al. mRNA vaccines expressing homo-prototype\/Omicron and hetero-chimeric RBD-dimers against SARS-CoV-2. Cell Res. 2022:1\u20134.","DOI":"10.1038\/s41422-022-00720-z"},{"issue":"3","key":"2023_CR79","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1128\/CMR.00072-15","volume":"29","author":"D Musso","year":"2016","unstructured":"Musso D, Gubler DJ. Zika virus. Clin Microbiol Rev. 2016;29(3):487\u2013524.","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"2023_CR80","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","volume":"168","author":"JM Richner","year":"2017","unstructured":"Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, et al. Modified mRNA vaccines protect against Zika virus infection. Cell. 2017;168(6):1114-1125.e1110.","journal-title":"Cell"},{"issue":"2","key":"2023_CR81","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.06.040","volume":"170","author":"JM Richner","year":"2017","unstructured":"Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, Himansu S, Caine EA, Nunes BTD, Medeiros DBA, et al. Vaccine mediated protection against Zika virus-induced congenital disease. Cell. 2017;170(2):273-283.e212.","journal-title":"Cell"},{"issue":"2","key":"2023_CR82","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.chom.2007.03.002","volume":"1","author":"TC Pierson","year":"2007","unstructured":"Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, Diamond MS. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe. 2007;1(2):135\u201345.","journal-title":"Cell Host Microbe"},{"issue":"2","key":"2023_CR83","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.virol.2010.12.020","volume":"411","author":"KA Dowd","year":"2011","unstructured":"Dowd KA, Pierson TC. Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology. 2011;411(2):306\u201315.","journal-title":"Virology"},{"key":"2023_CR84","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.3389\/fimmu.2019.01424","volume":"10","author":"C Roth","year":"2019","unstructured":"Roth C, Cantaert T, Colas C, Prot M, Casad\u00e9mont I, Levillayer L, Thalmensi J, Langlade-Demoyen P, Gerke C, Bahl K, et al. A Modified mRNA vaccine targeting immunodominant NS epitopes protects against dengue virus infection in HLA Class I transgenic mice. Front Immunol. 2019;10:1424.","journal-title":"Front Immunol"},{"issue":"7624","key":"2023_CR85","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nature19790","volume":"538","author":"EC Holmes","year":"2016","unstructured":"Holmes EC, Dudas G, Rambaut A, Andersen KG. The evolution of Ebola virus: insights from the 2013\u20132016 epidemic. Nature. 2016;538(7624):193\u2013200.","journal-title":"Nature"},{"issue":"1","key":"2023_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2014.11.008","volume":"93","author":"E De Clercq","year":"2015","unstructured":"De Clercq E. Ebola virus (EBOV) infection: therapeutic strategies. Biochem Pharmacol. 2015;93(1):1\u201310.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2023_CR87","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1128\/JCM.03115-14","volume":"53","author":"EM Burd","year":"2015","unstructured":"Burd EM. Ebola virus: a clear and present danger. J Clin Microbiol. 2015;53(1):4\u20138.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"2023_CR88","first-page":"57","volume":"54","author":"B Zawili\u0144ska","year":"2014","unstructured":"Zawili\u0144ska B, Kosz-Vnenchak M. General introduction into the Ebola virus biology and disease. Folia Med Cracov. 2014;54(3):57\u201365.","journal-title":"Folia Med Cracov"},{"issue":"3","key":"2023_CR89","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/infdis\/jix592","volume":"217","author":"M Meyer","year":"2018","unstructured":"Meyer M, Huang E, Yuzhakov O, Ramanathan P, Ciaramella G, Bukreyev A. Modified mRNA-based vaccines elicit robust immune responses and protect Guinea Pigs from Ebola virus disease. J Infect Dis. 2018;217(3):451\u20135.","journal-title":"J Infect Dis"},{"key":"2023_CR90","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1146\/annurev-med-120617-041310","volume":"71","author":"R Nachbagauer","year":"2020","unstructured":"Nachbagauer R, Palese P. Is a universal influenza virus vaccine possible? Annu Rev Med. 2020;71:315\u201327.","journal-title":"Annu Rev Med"},{"issue":"6","key":"2023_CR91","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","volume":"25","author":"K Bahl","year":"2017","unstructured":"Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, Laska ME, Smith M, Almarsson \u00d6, Thompson J, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther. 2017;25(6):1316\u201327.","journal-title":"Mol Ther"},{"issue":"25","key":"2023_CR92","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","volume":"37","author":"RA Feldman","year":"2019","unstructured":"Feldman RA, Fuhr R, Smolenov I, Mick Ribeiro A, Panther L, Watson M, Senn JJ, Smith M, Almarsson \u04e6, Pujar HS, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37(25):3326\u201334.","journal-title":"Vaccine"},{"issue":"2","key":"2023_CR93","first-page":"323","volume":"37","author":"AC Banyard","year":"2018","unstructured":"Banyard AC, Tordo N. Rabies pathogenesis and immunology. Revue scientifique et technique (International Office of Epizootics). 2018;37(2):323\u201330.","journal-title":"Revue scientifique et technique (International Office of Epizootics)"},{"issue":"1","key":"2023_CR94","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1146\/annurev-virology-100114-055157","volume":"2","author":"BM Davis","year":"2015","unstructured":"Davis BM, Rall GF, Schnell MJ. Everything you always wanted to know about rabies virus (but were afraid to ask). Annu Rev Virol. 2015;2(1):451\u201371.","journal-title":"Annu Rev Virol"},{"issue":"10101","key":"2023_CR95","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","volume":"390","author":"M Alberer","year":"2017","unstructured":"Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, Gottardo R, Bica MA, Garofano A, Koch SD, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet (London, England). 2017;390(10101):1511\u201320.","journal-title":"Lancet (London, England)"},{"issue":"12","key":"2023_CR96","doi-asserted-by":"publisher","first-page":"e0006108","DOI":"10.1371\/journal.pntd.0006108","volume":"11","author":"L Stitz","year":"2017","unstructured":"Stitz L, Vogel A, Schnee M, Voss D, Rauch S, Mutzke T, Ketterer T, Kramps T, Petsch B. A thermostable messenger RNA based vaccine against rabies. PLoS Negl Trop Dis. 2017;11(12):e0006108\u2013e0006108.","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"2023_CR97","first-page":"5","volume":"46","author":"E Fanales-Belasio","year":"2010","unstructured":"Fanales-Belasio E, Raimondo M, Suligoi B, Butt\u00f2 S. HIV virology and pathogenetic mechanisms of infection: a brief overview. Annali dell\u2019Istituto superiore di sanita. 2010;46(1):5\u201314.","journal-title":"Annali dell'Istituto superiore di sanita"},{"issue":"9534","key":"2023_CR98","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0140-6736(06)69157-5","volume":"368","author":"V Simon","year":"2006","unstructured":"Simon V, Ho DD, Abdool Karim Q. HIV\/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet (London, England). 2006;368(9534):489\u2013504.","journal-title":"Lancet (London, England)"},{"issue":"7","key":"2023_CR99","first-page":"e16197","volume":"13","author":"K Khalid","year":"2021","unstructured":"Khalid K, Padda J, Khedr A, Ismail D, Zubair U, Al-Ewaidat OA, Padda S, Cooper AC, Jean-Charles G. HIV and messenger RNA (mRNA) vaccine. Cureus. 2021;13(7):e16197\u2013e16197.","journal-title":"Cureus"},{"issue":"1","key":"2023_CR100","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/QAI.0000000000000926","volume":"72","author":"JM Jacobson","year":"2016","unstructured":"Jacobson JM, Routy J-P, Welles S, DeBenedette M, Tcherepanova I, Angel JB, Asmuth DM, Stein DK, Baril J-G, McKellar M, et al. Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: a randomized, double-blind, placebo-controlled clinical trial. J Acquir Immune Defic Syndr. 2016;72(1):31\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"2023_CR101","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.3109\/10717544.2015.1038856","volume":"23","author":"M Zhao","year":"2016","unstructured":"Zhao M, Li M, Zhang Z, Gong T, Sun X. Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA. Drug Delivery. 2016;23(7):2596\u2013607.","journal-title":"Drug Delivery"},{"key":"2023_CR102","doi-asserted-by":"crossref","unstructured":"Sun C, Zuo T, Wen Z. First clinical study of germline-targeting strategy: One step closer to a successful bnAb-based HIV vaccine. Innovation (Cambridge (Mass)) 2023;4(1):100374.","DOI":"10.1016\/j.xinn.2023.100374"},{"issue":"2","key":"2023_CR103","volume":"10","author":"A Fortner","year":"2022","unstructured":"Fortner A, Bucur O. mRNA-based vaccine technology for HIV. Discoveries (Craiova, Romania). 2022;10(2): e150.","journal-title":"Discoveries (Craiova, Romania)"},{"key":"2023_CR104","doi-asserted-by":"crossref","unstructured":"Nowalk A, Green M: Epstein-Barr Virus. Microbiol Spectrum 2016;4(3).","DOI":"10.1128\/microbiolspec.DMIH2-0011-2015"},{"issue":"3","key":"2023_CR105","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/jmv.24633","volume":"89","author":"M Neves","year":"2017","unstructured":"Neves M, Marinho-Dias J, Ribeiro J, Sousa H. Epstein-Barr virus strains and variations: Geographic or disease-specific variants? J Med Virol. 2017;89(3):373\u201387.","journal-title":"J Med Virol"},{"issue":"1","key":"2023_CR106","first-page":"273","volume":"1868","author":"H Foster","year":"2017","unstructured":"Foster H, Ulasov IV, Cobbs CS. Human cytomegalovirus-mediated immunomodulation: effects on glioblastoma progression. Biochim Biophys Acta. 2017;1868(1):273\u20136.","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"2023_CR107","doi-asserted-by":"publisher","first-page":"911.e911","DOI":"10.1016\/j.amjmed.2006.12.011","volume":"120","author":"C Hurt","year":"2007","unstructured":"Hurt C, Tammaro D. Diagnostic evaluation of mononucleosis-like illnesses. Am J Med. 2007;120(10):911.e911-918.","journal-title":"Am J Med"},{"key":"2023_CR108","doi-asserted-by":"crossref","unstructured":"Dioverti MV, Razonable RR: Cytomegalovirus. Microbiol Spectrum 2016;4(4).","DOI":"10.1128\/microbiolspec.DMIH2-0022-2015"},{"issue":"7","key":"2023_CR109","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/gt.2011.17","volume":"18","author":"M Diken","year":"2011","unstructured":"Diken M, Kreiter S, Selmi A, Britten CM, Huber C, T\u00fcreci \u00d6, Sahin U. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther. 2011;18(7):702\u20138.","journal-title":"Gene Ther"},{"issue":"20","key":"2023_CR110","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.1158\/1078-0432.CCR-20-1082","volume":"26","author":"KA Batich","year":"2020","unstructured":"Batich KA, Mitchell DA, Healy P, Herndon JE 2nd, Sampson JH. Once, twice, three times a finding: reproducibility of dendritic cell vaccine trials targeting cytomegalovirus in glioblastoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2020;26(20):5297\u2013303.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"12","key":"2023_CR111","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","volume":"36","author":"S John","year":"2018","unstructured":"John S, Yuzhakov O, Woods A, Deterling J, Hassett K, Shaw CA, Ciaramella G. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine. 2018;36(12):1689\u201399.","journal-title":"Vaccine"},{"issue":"11","key":"2023_CR112","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/apm.12990","volume":"127","author":"S Kares","year":"2019","unstructured":"Kares S, Veijalainen O, Kholov\u00e1 I, Tirkkonen M, Vuento R, Huhtala H, Tuimala V, M\u00e4enp\u00e4\u00e4 J, Kujala P. HIGH-RISK HPV testing as the primary screening method in an organized regional screening program for cervical cancer: the value of HPV16 and HPV18 genotyping? APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 2019;127(11):710\u20136.","journal-title":"APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica"},{"issue":"8","key":"2023_CR113","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s00262-021-03134-9","volume":"71","author":"N Salomon","year":"2022","unstructured":"Salomon N, Selmi A, Grunwitz C, Kong A, Stanganello E, Neumaier J, Petschenka J, Diken M, Kreiter S, T\u00fcreci \u00d6, et al. Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16(+) cancer. Cancer Immunol Immunother: CII. 2022;71(8):1975\u201388.","journal-title":"Cancer Immunol Immunother: CII"},{"key":"2023_CR114","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.trsl.2021.12.006","volume":"242","author":"S Awasthi","year":"2022","unstructured":"Awasthi S, Friedman HM. An mRNA vaccine to prevent genital herpes. Transl Res. 2022;242:56\u201365.","journal-title":"Transl Res"},{"key":"2023_CR115","doi-asserted-by":"crossref","unstructured":"Awasthi S, Hook LM, Pardi N, Wang F, Myles A, Cancro MP, Cohen GH, Weissman D, Friedman HM. Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Sci Immunol. 2019;4(39):eaaw7083.","DOI":"10.1126\/sciimmunol.aaw7083"},{"key":"2023_CR116","doi-asserted-by":"crossref","unstructured":"Awasthi S, Knox JJ, Desmond A, Alameh MG, Gaudette BT, Lubinski JM, Naughton A, Hook LM, Egan KP, Tam YK et al. Trivalent nucleoside-modified mRNA vaccine yields durable memory B cell protection against genital herpes in preclinical models. J Clin Investig. 2021;131(23).","DOI":"10.1172\/JCI152310"},{"issue":"6","key":"2023_CR117","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/ACI.0000000000000315","volume":"16","author":"A Matucci","year":"2016","unstructured":"Matucci A, Nencini F, Pratesi S, Maggi E, Vultaggio A. An overview on safety of monoclonal antibodies. Curr Opin Allergy Clin Immunol. 2016;16(6):576\u201381.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"16","key":"2023_CR118","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1056\/NEJMp1802256","volume":"378","author":"HD Marston","year":"2018","unstructured":"Marston HD, Paules CI, Fauci AS. Monoclonal antibodies for emerging infectious diseases - borrowing from history. N Engl J Med. 2018;378(16):1469\u201372.","journal-title":"N Engl J Med"},{"issue":"3","key":"2023_CR119","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2471\/BLT.16.178061","volume":"95","author":"E Sparrow","year":"2017","unstructured":"Sparrow E, Friede M, Sheikh M, Torvaldsen S. Therapeutic antibodies for infectious diseases. Bull World Health Organ. 2017;95(3):235\u20137.","journal-title":"Bull World Health Organ"},{"issue":"1","key":"2023_CR120","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.chom.2015.06.009","volume":"18","author":"SA Smith","year":"2015","unstructured":"Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Ashbrook AW, Kahle KM, Fong RH, et al. Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against Chikungunya virus. Cell Host Microbe. 2015;18(1):86\u201395.","journal-title":"Cell Host Microbe"},{"key":"2023_CR121","doi-asserted-by":"crossref","unstructured":"Kose N, Fox JM, Sapparapu G, Bombardi R, Tennekoon RN, de Silva AD, Elbashir SM, Theisen MA, Humphris-Narayanan E, Ciaramella G et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci Immunol. 2019;4(35).","DOI":"10.1126\/sciimmunol.aaw6647"},{"issue":"1","key":"2023_CR122","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12967-019-1804-8","volume":"17","author":"L Van Hoecke","year":"2019","unstructured":"Van Hoecke L, Roose K. How mRNA therapeutics are entering the monoclonal antibody field. J Transl Med. 2019;17(1):54.","journal-title":"J Transl Med"},{"key":"2023_CR123","first-page":"81","volume":"435","author":"VR DeFilippis","year":"2022","unstructured":"DeFilippis VR. Chikungunya virus vaccines: platforms, progress, and challenges. Curr Top Microbiol Immunol. 2022;435:81\u2013106.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"12","key":"2023_CR124","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078\u201394.","journal-title":"Nat Rev Mater"},{"issue":"4","key":"2023_CR125","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41422-022-00630-0","volume":"32","author":"YQ Deng","year":"2022","unstructured":"Deng YQ, Zhang NN, Zhang YF, Zhong X, Xu S, Qiu HY, Wang TC, Zhao H, Zhou C, Zu SL, et al. Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters. Cell Res. 2022;32(4):375\u201382.","journal-title":"Cell Res"},{"key":"2023_CR126","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.omtn.2020.04.015","volume":"20","author":"L Van Hoecke","year":"2020","unstructured":"Van Hoecke L, Verbeke R, De Vlieger D, Dewitte H, Roose K, Van Nevel S, Krysko O, Bachert C, Schepens B, Lentacker I, et al. mRNA Encoding a bispecific single domain antibody construct protects against influenza A virus infection in mice. Mol Ther Nucleic Acids. 2020;20:777\u201387.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2023_CR127","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.omtm.2020.06.011","volume":"18","author":"JH Erasmus","year":"2020","unstructured":"Erasmus JH, Archer J, Fuerte-Stone J, Khandhar AP, Voigt E, Granger B, Bombardi RG, Govero J, Tan Q, Durnell LA, et al. Intramuscular delivery of replicon RNA encoding ZIKV-117 human monoclonal antibody protects against Zika virus Infection. Mol Therapy Methods Clin Develop. 2020;18:402\u201314.","journal-title":"Mol Therapy Methods Clin Develop"},{"issue":"1","key":"2023_CR128","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1038\/s41467-018-06508-3","volume":"9","author":"PM Tiwari","year":"2018","unstructured":"Tiwari PM, Vanover D, Lindsay KE, Bawage SS, Kirschman JL, Bhosle S, Lifland AW, Zurla C, Santangelo PJ. Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection. Nat Commun. 2018;9(1):3999.","journal-title":"Nat Commun"},{"key":"2023_CR129","doi-asserted-by":"crossref","unstructured":"Hotz C, Wagenaar TR, Gieseke F, Bangari DS, Callahan M, Cao H, Diekmann J, Diken M, Grunwitz C, Hebert A et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci Transl Med. 2021;13(610):eabc7804.","DOI":"10.1126\/scitranslmed.abc7804"},{"issue":"1","key":"2023_CR130","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-021-01329-3","volume":"20","author":"L Van Hoecke","year":"2021","unstructured":"Van Hoecke L, Verbeke R, Dewitte H, Lentacker I, Vermaelen K, Breckpot K, Van Lint S. mRNA in cancer immunotherapy: beyond a source of antigen. Mol Cancer. 2021;20(1):48.","journal-title":"Mol Cancer"},{"key":"2023_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2022.113008","volume":"164","author":"S Seneff","year":"2022","unstructured":"Seneff S, Nigh G, Kyriakopoulos AM, McCullough PA. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs. Food Chem Toxicol: Int Publ Bt Ind Biol Res Assoc. 2022;164: 113008.","journal-title":"Food Chem Toxicol: Int Publ Bt Ind Biol Res Assoc"},{"key":"2023_CR132","doi-asserted-by":"crossref","unstructured":"Blakney AK, Ip S, Geall AJ. An update on self-amplifying mRNA vaccine development. Vaccines (Basel) 2021, 9(2).","DOI":"10.3390\/vaccines9020097"},{"key":"2023_CR133","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","volume":"170","author":"J Kim","year":"2021","unstructured":"Kim J, Eygeris Y, Gupta M, Sahay G. Self-assembled mRNA vaccines. Adv Drug Deliv Rev. 2021;170:83\u2013112.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"2023_CR134","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1080\/17460441.2021.1935859","volume":"16","author":"KKW To","year":"2021","unstructured":"To KKW, Cho WCS. An overview of rational design of mRNA-based therapeutics and vaccines. Expert Opin Drug Discov. 2021;16(11):1307\u201317.","journal-title":"Expert Opin Drug Discov"},{"issue":"10","key":"2023_CR135","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","volume":"185","author":"L Qu","year":"2022","unstructured":"Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y, Wu Z, Tang H, Zhang X, Tian F, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185(10):1728-1744.e1716.","journal-title":"Cell"},{"issue":"7","key":"2023_CR136","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A, Peacock SJ, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409\u201324.","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"2023_CR137","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.molmed.2017.01.006","volume":"23","author":"A De Beuckelaer","year":"2017","unstructured":"De Beuckelaer A, Grooten J, De Koker S. Type I Interferons modulate CD8(+) T cell immunity to mRNA vaccines. Trends Mol Med. 2017;23(3):216\u201326.","journal-title":"Trends Mol Med"},{"issue":"3","key":"2023_CR138","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jhep.2022.03.040","volume":"77","author":"T Boettler","year":"2022","unstructured":"Boettler T, Csernalabics B, Sali\u00e9 H, Luxenburger H, Wischer L, Salimi Alizei E, Zoldan K, Krimmel L, Bronsert P, Schwabenland M, et al. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. J Hepatol. 2022;77(3):653\u20139.","journal-title":"J Hepatol"},{"issue":"4","key":"2023_CR139","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.jaip.2020.12.047","volume":"9","author":"A Banerji","year":"2021","unstructured":"Banerji A, Wickner PG, Saff R, Stone CA Jr, Robinson LB, Long AA, Wolfson AR, Williams P, Khan DA, Phillips E, et al. mRNA Vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021;9(4):1423\u201337.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2023_CR140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijid.2021.08.048","volume":"111","author":"CS van Dam","year":"2021","unstructured":"van Dam CS, Lede I, Schaar J, Al-Dulaimy M, R\u00f6sken R, Smits M. Herpes zoster after COVID vaccination. Int J Infect Diseases: IJID: Off Publ Int Soc Infect Diseases. 2021;111:169\u201371.","journal-title":"Int J Infect Diseases: IJID: Off Publ Int Soc Infect Diseases"},{"issue":"10","key":"2023_CR141","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41589-022-01094-4","volume":"18","author":"Z Cui","year":"2022","unstructured":"Cui Z, Zeng C, Huang F, Yuan F, Yan J, Zhao Y, Zhou Y, Hankey W, Jin VX, Huang J, et al. Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection. Nat Chem Biol. 2022;18(10):1056\u201364.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"2023_CR142","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41392-021-00634-z","volume":"6","author":"R Yang","year":"2021","unstructured":"Yang R, Deng Y, Huang B, Huang L, Lin A, Li Y, Wang W, Liu J, Lu S, Zhan Z, et al. A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Signal Transduct Target Ther. 2021;6(1):213.","journal-title":"Signal Transduct Target Ther"},{"key":"2023_CR143","doi-asserted-by":"crossref","unstructured":"August A, Shaw CA, Lee H, Knightly C, Kalidindia S, Chu L, Essink BJ, Seger W, Zaks T, Smolenov I et al. Safety and immunogenicity of an mRNA-based human metapneumovirus and parainfluenza virus type 3 combined vaccine in healthy adults. Open Forum Infect Diseases 2022;9(7):ofac206.","DOI":"10.1093\/ofid\/ofac206"},{"issue":"1","key":"2023_CR144","doi-asserted-by":"publisher","first-page":"7105","DOI":"10.1038\/s41467-021-27316-2","volume":"12","author":"M Haranaka","year":"2021","unstructured":"Haranaka M, Baber J, Ogama Y, Yamaji M, Aizawa M, Kogawara O, Scully I, Lagkadinou E, T\u00fcreci \u04e6, \u015eahin U, et al. A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nat Commun. 2021;12(1):7105.","journal-title":"Nat Commun"},{"issue":"9","key":"2023_CR145","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.7326\/M22-1300","volume":"175","author":"D Follmann","year":"2022","unstructured":"Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, Kotloff K, Desjardins M, Corey L, Neuzil KM, et al. Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial. Ann Intern Med. 2022;175(9):1258\u201365.","journal-title":"Ann Intern Med"},{"issue":"3","key":"2023_CR146","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/QAI.0000000000000852","volume":"71","author":"RT Gandhi","year":"2016","unstructured":"Gandhi RT, Kwon DS, Macklin EA, Shopis JR, McLean AP, McBrine N, Flynn T, Peter L, Sbrolla A, Kaufmann DE, et al. Immunization of HIV-1-infected persons with autologous dendritic cells transfected with mRNA encoding HIV-1 Gag and Nef: results of a randomized, placebo-controlled clinical trial. J Acquir Immune Defic Syndr. 2016;71(3):246\u201353.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"2023_CR147","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s13063-019-3409-1","volume":"20","author":"W de Jong","year":"2019","unstructured":"de Jong W, Aerts J, Allard S, Brander C, Buyze J, Florence E, van Gorp E, Vanham G, Leal L, Mothe B, et al. iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. Trials. 2019;20(1):361.","journal-title":"Trials"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-023-02023-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-023-02023-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-023-02023-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T14:04:08Z","timestamp":1680876248000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-023-02023-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":147,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2023"],"URL":"https:\/\/doi.org\/10.1186\/s12985-023-02023-0","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]},"assertion":[{"value":"21 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}